



**MEMORANDUM**

**Date:** 27 July, 2016

**From:** Karen Campbell  
Division of Biological Standards and Quality Control (DBSQC)  
Office of Compliance and Biologics Quality (OCBQ)  
Center for Biologics Evaluation and Research (CBER)  
Food and Drug Administration (FDA)

**To:** **Biologics License Application Submission Tracking Number # 125596/0**

**Subject:** **Review of Lot Release Protocol Templates for Drug Product of Biologics License Application for Immune Globulin Subcutaneous (Human), 20% Solution**

**Through:** William M. McCormick, Ph.D., Director, DBSQC/OCBQ/CBER/FDA

**Cc:** Thomas Maruna, RPM, OBRR  
Jennifer Reed, Chair, BLA Review Committee, DHRR/OBRR

**Applicant:** Baxalta US Inc.

**Product:** Immune Globulin Subcutaneous (Human), 20% Solution

## **1 General Information**

### **1.1 CMC Review Identifiers and Dates**

#### **1.1.1 Biologics License Application (BLA) Submission Tracking Number (STN) #: 125596**

#### **1.1.2 Submission received by CBER: Sep 14, 2015**

#### **1.1.3 Review completed: Jun 30, 2016**

#### **1.1.4 Material Reviewed**

**Original BLA:** The following general module sections of the BLA were reviewed: M3 CMC, Quality

**2 Executive Summary:** The lot release protocol template submitted in 125596/0.25 is acceptable for use.

## **3 Review**

### **3.1 Documents Reviewed**

1. Lot Release Protocol Template submitted in 3.2R Regional Information, in amendment 125596/0.1
2. Amendment 125596/0.24 Lot Release Protocol Template
3. Amendment 125596/0.25 Lot Release Protocol Template

### **3.2 Review**

The lot release protocol template submitted in amendment 125596/0.1 was reviewed by DBSQC, the product chair and the Product Release Branch. The following comments were sent to Baxalta.

We are reviewing your October 14, 2016, Lot Release Protocol Template submission to your BLA for Immune Globulin Subcutaneous (Human), 20% Solution.

We are providing the following comments and request for additional information to continue our review:

1. On each page, in the header, the CC line is missing from the protocol. It must be at the top of the each page and in the following format “cc: STN#-0/license #/product type (FC, B, etc.)”

2. On page 2 of 4, please include the date test completed for each of the tests.
3. On page 2 of 2, please include the (b) (4) Assay, including the results (in U/ml) and the specifications ((b) (4) ) for the test.
4. On page 4 of 4 for Sterility, please add additional information. Please see the attached example of a suggested template for this information.
  - a. Please add the (b) (4) test date, above the table
  - b. The Type of sample (i.e., bulk, final container) above the table
  - c. The quantities tested per media type (as part of the table)
  - d. Result (pass/fail) below the table
  - e. Specification ((b) (4) ) below the table
5. Please include more information on the Bacterial Endotoxins test performed. Please see the attached example of a suggested template for this information.

Responses to our requests and a revised lot release protocol were received on 16-May-2016, in amendment 125596/0.23. Baxalta indicated that they had revised the Immunglobulin subcutaneous (IGSC) 20% lot release protocol as indicated. Prior to initiating a review, in response to draft post marketing commitments Baxalta sent a revised lot release protocol template in amendment 125596/0.24. The Lot Release Protocol template was reviewed and the following comments were sent to Baxalta.

1. On page 3 of 5, in the sterility template, please confirm that the specification will be No growth and please state the result as growth or no growth.
2. On page 5 of 5, the signature is not needed

Baxalta responded to our request and submitted a revised lot release protocol on 20-Jun-2016 in amendment 125596/0.25. This was reviewed and found acceptable for use.

### **3.3 Conclusions**

The lot release protocol template submitted in 125596/0.25 and reviewed by DBSQC, PRB and the chair of the BLA and was found to be acceptable for use.